Hyperplasia, FEA, ADH, and Lobular neoplasia

> Abeer Shaaban Consultant Pathologist Queen Elizabeth Hospital Birmingham



Rakha E, Diagnostic Histopathology 2012

Intraductal Epithelial proliferation

Ductal or lobular
Atypical or not
Extent of atypia



Non atypical ductal hyperplasia

(Epithelial hyperplasia of usual type, Usual ductal hyperplasia)

Architecture: solid with peripheral slit like spaces, streaming of nuclei.

Cytological: mixed population
Rounded and ovoid cells
Variation in size and shape









Epithelial hyperplasia

Papilloma Columnar cell change Radial scar Fibroadenoma Apocrine metaplasia Nipple adenoma Gynaecomastia





Quantitative diagnosis

Not high grade

If on core biopsy: designate as AIDEP



Architectural atypia









Fauna-form changes in the breast Shamonki et al Am J Surg Pathol 2006





C

d

ADH vs DCIS

Extent of atypia: 2mm or 2 fully involved ductal spaces = DCIS (NOT FOR HIGH GRADE LESIONS)

Atypia in papillomas: 3mm



Useful Immunohistochemistry

	Hyperplasia	ADH/DCIS
CK5	mixed	Negative
ER	Patchy positive	Uniformly positive





ER











HER2 IHC can be helpful in confirming the diagnosis of DCIS

IHC Pitfalls

1. Apocrine lesions

Apocrine metaplasia



Atypical apocrine proliferation





2. Basal phenotype DCIS





3. Hyperplasia in the male breast



Kornegoor et al Am J Surg Pathol 2012

Circulation group	Benign	Atypical hyperplasia	In situ/micro-invasive	Invasive
No of cases				
19 902-20 002	60	5	62	125
20 011-20 141	112	6	36	170
Total	172	11	98	295
Circulations				
19 902-20 002	0.79	0.18	0.76	0.88
20 011-20 021	0.83	0.15	0.83	0.96
20 022-20 032	0.79	0.18	0.75	0.90
20 041-20 051	0.70	0.20	0.65	0.90
20 052-200 62	0.87	0.19	0.78	0.96
20 071 –20 081	0.82	0.10	0.70	0.92
20 082-20 092	0.76	0.17	0.23	0.89
20 101-20 111	0.83	0.14	0.44	0.92
20 1 12 - 20 1 22	0.79	0.18	0.75	0.90
20 1 31 - 20 1 41	0.81	0.13	0.83	0.95
20 011-20 141	0.81	0.17	0.72	0.92
Overall				
19 902-20 1 41	0.80	0.17*	0.75	0.91

Table 1 κ Values for overall diagnosis (all participants)

Rakha et al 2016

Flat epithelial atypia

Columnar cell lesions

 Columnar cell change (without atypia): columnar cell change/columnar cell hyperplasia

Flat epithelial atypia

If high grade nuclei = flat DCIS

FEA: WHO 2012 Definition

A neoplastic proliferation of TDLUs characterised by replacement of the native epithelial cells by one to several layers of a single epithelial cell type showing low grade (monomorphic) cytological atypia
Previous terminology of FEA

- Atypical lobule type A
- Atypical columnar cell metaplasia
- Atypical cystic lobules
- Atypical cystic duct
- Hypersecretory hyperplasia with atypia
- Columnar cell change with atypia
- DIN (DIN1a = FEA)
- Clinging carcinoma (monomorphic type)
- Monomorphic epithelial proliferation

Columnar cell change

- Dilated TDLU (oval/branching)
- Columnar cells with polarity
- Apical snouts
- ±Calcification
- ER positive, CK5 negative





FEA

- Dilated TDLU, regular/rounded acini
- Round/oval nuclei
- Monotonous nuclei with loss of polarity
- Cytological atypia, often hyperchromasia
- Usually with apical snouts
- May have small nucleoli
- ER positive, CK5 negative

No high grade atypia or complex architecture





















FEA Immunohistochemical profile

ER, PR +, Bcl2+
CK5 –
Her 2 negative

Similar to ADH and low grade DCIS

FEA diagnosis is morphological





FEA Reproducibility of Diagnosis

Poor agreement on assessment of images by a mixed group of pathologists

Tan et al., . Pathological diagnosis of columnar cell lesions of the breast: are there issues of reproducibility? J Clin Pathol 2005;58(7):705-9.

 Excellent agreement among breast pathologists after PowerPoint training session (better for exclusion of atypia)

O'Malley et al. Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breast. Mod Pathol 2006;19(2):172-9

Tips

Do not over-diagnose atypia

Discuss with colleagues!

Rosen's triad

Columnar cell lesions, lobular neoplasia, tubular carcinoma



Associated lesions Low nuclear grade neoplasia family

-Tubular, cribriform, grade 1 ductal NST, lobular, tubulolobular carcinoma

-CCC, FEA, ADH, low grade DCIS, lobular in situ neoplasia

-ER, bcl2, CK8, 18, 19 positive. CK5, 14, p53, HER2 neg

Abdel-Fatah et al, Am J Surg Pathol 2008



Lobular neoplasia

Encompasses atypical lobular hyperplasia
 (ALH) and lobular in situ carcinoma
 (LCIS).

LCIS: classical and variants

ALH vs LCIS

Depends on extent of lesion

 LCIS: more than half of the acini are filled, distended and distorted by the dyscohesive lobular cells.



Histologically

A monomorphic proliferation within TDLU of dyscohesive cells with uniform round nuclei, indistinct nucleoli and scant cytoplasm.

Intracytoplasmic lumina are often present

Pagetoid spread can be seen.

• Type A cells: small uniform cells with bland nuclei and scant cytoplasm

• Type B cells: cells are larger, with more cytoplasm and mild to moderate atypia







Immunohistochemistry

E-cadherin: negative (but not always) CK5, CK14: negative ER: positive Her2: negative Loss of β-catenin Cytoplasmic catenin p120: indicates ecadherin complex is dysfunctional






The diagnosis of lobular neoplasia is morphological.

 E-cadherin is often negative (but not always) in invasive lobular carcinoma.

 Expression may be diminished, aberrant or heterogeneous.

 Bcatenin (neg)and p120 (cytoplasmic) may be helpful in difficult cases

Histopathology

Histopethology 2016, 68, 57-69, DOI: 10.1111/his.12869

REVIEW

E-cadherin immunohistochemistry in breast pathology: uses and pitfalls

Rita Canas-Marques & Stuart J Schnitt¹

Department of Pathology, Champalimaud Foundation, Lisboa, Portugal, and ¹Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

> First author No. (%) E-cadher/n-positive l(uroda¹⁹ 0 of 20 (0%) Sutonen²⁰ 0 of 55 (0%) Acc^{21} 1 of 42 (2.4%) Goldstein²² 5 of 143 (3.5%) Qurestv²⁹ 5 of 44 (11.4%) Da Silva¹⁷ 4 of 25 (16%) Rakba¹⁸ 38 of 239 (15.9%) Samo²⁴ 12 of 51 (23.5%) 65 of 619 (10.5%) Total

> Table 2. Frequency of aberrant E-cadherin expression ininvasive lobular carinomas in series with at least 20 cases





Variants of LCIS

Pleomorphic LCIS (PLCIS)

PLCIS Definition

Similar to Rosen's criteria for classic LCIS:

lobular units expanded by dyscohesive, pleomorphic cells with abundant eosinophilic cytoplasm, grade 3 nuclei, and prominent nucleoli (Chivukula et al 2008)

PLCIS

Recently recognized variant of Lobular Carcinoma In Situ (LCIS) May calcify hence present through breast screening Biology and natural history uncertain Histologically: mimics high grade CIS







Pleomorphic apocrine LCIS PAL-CIS

- Chen et al 2005 (suppl) described 10 cases
- Pleomorphic apocrine LCIS: LCIS with myxoid, apocrine and pleomorphic cytology
- CGH: Loss of 16Q, gain at 1Q
- DD apocrine DCIS with involvement of lobules



Immunohistochemistry of PLCIS

E-CADHERIN NEGATIVE

OESTROGEN RECEPTOR may be POSITIVE OR NEGATIVE

 GCDFP-15 OFTEN POSITIVE- may be helpful in histological diagnosis

HER-2 may be POSITIVE

 P120 catenin: cytoplasmic staining in LCIS, membranous in ductal







PLCIS within background of LCIS



PLCIS (ER neg) with conventional LCIS (ER pos) Carder et al 2010





Rare variant of LCIS

Classical LCIS with comedo necrosis (Mass forming LCIS, Florid LCIS







CALL .

Sapino et al 2000 described 10 cases of LCIS with necrosis, 4 of which associated with invasive carcinoma

A study of 18 cases reported a strong association with invasive cancer (67% of cases) Fadare et al Am J Surg Pathol 2006 30:1445–1453

Chin et al 2013 examined the genetic profile of 20 cases of "Florid LCIS". Lesions showed loss of 16q (all cases) and 1q gain (80%)

UK multicentre series



Association with malignancy 53.6%

Upgrade following core biopsy diagnosis: 35.7%

Associated invasive: predominantly lobular

Shaaban et al., manuscript in preparation

Diagnostic challenges

Is the proliferation ductal or lobular?

(Low/intermediate grade DCS VS LCIS) (High grade DCIS VS PLCIS)



Cellular cohesion

Architectural pattern of DCIS

E-cadherin IHC can help

Are the nuclei pleomorphic enough to designate as PLCIS?

Compare size with normal ductal epithelial cell.

■ IHC: ER, GCDFP-15, HER2 may help







DOI 10.1007/s10549 017 4334 1



EPIDEMIOLOGY

Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review

Marina De Brot¹ · Starr Koslow Mautner² · Shirin Muhsen² · Victor P. Andrade¹ · Anita Mamtani² · Melissa Murray³ · Dilip Giri³ · Rita A. Sakr² · Edi Brogi³ · Tari A. King^{4,5}

Received: 1 June 2017/Accepted: 7 June 2017 © Springer Science+Business Media, LLC 2017

New terminology from MSKCC

LCIS-PF: LCIS with pleomorphic features



In situ carcinoma with mixed ductal and lobular features

 E cadherin IHC may show heterogeneous staining (DD positive residual cells)

Schnitt group: Jacobs et al Carcinomas in situ of the breast with indeterminate features: role of Ecadherin staining in categorization. Am J Surg Pathol 2001;25:229–236.





Clinical relevance

Lesion	Relative risk	Upgrade risk	
FEA	X2	13-21%, average 15% (in pure	
		form); if co-existent with	
		AIDEP then higher risk:	
		pooled 29%	
AIDEP	x4.4-5	37-53 %, pooled value 21%	
	x8 if FH	after VAB	
ALH	x4-5	0-43%, pooled data 19%	
LCIS	x8-10	0-60, pooled value 27%	Pind boo
			- 000

Pinder and Shaaban, book chapter 2017

B - Categorisation

Epithelial hyperplasia, no atypia: B2

FEA, AIDEP, Lobular neoplasia: B3

DCIS/PLCIS: B5a

LCIS with necrosis: best coded as B4

Lobular neoplasia on core biopsy

ALH/Classical LCIS: code as B3 and recommend second line VAB

PLCIS: code as B5a and manage as DCIS

 Classical LCIS with necrosis: rare, best coded as B4, recommend surgical excision.

PLCIS on excision

Sample well to exclude invasion
Assess lesion size, relation to margin
If associated with invasion: include size in whole tumour size

If at margin: re-excision



THANK YOU